Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 17/20 | 0.59 |
| ▸ | NOS1 | P29475 | 12/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559051 | 0.94 | NOS2 (0.51) | NOS2NOS1BRD4L3MBTL1 | |
| SCHEMBL3560275 | 0.78 | STK17B (0.46) | BRD4TDP1 | |
| SCHEMBL13037136 | 0.74 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL3562106 | 0.73 | NOS2 (0.80) | NOS2NOS1 | |
| SCHEMBL13037158 | 0.72 | NOS2 (0.54) | NOS2NOS1L3MBTL1 | |
| SCHEMBL3562730 | 0.72 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL3568935 | 0.72 | NOS2 (0.57) | NOS2NOS1 | |
| SCHEMBL3556118 | 0.71 | NOS2 (0.79) | NOS2NOS1 | |
| Iodide SCHEMBL2425744 | 0.70 | L3MBTL1 (0.49) | L3MBTL1TDP1 | |
| SCHEMBL4781044 | 0.70 | L3MBTL1 (0.60) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100094021-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100094021-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100094021-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1954695-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5-YL)-DIALKYL-AMINES | Kalypsys, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007062411-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5-YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094021-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | DCLK2, TH, DCLK3 | NOS2 983/4885NOS1 777/4885BRD4 181/4885 |
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | DCLK2, TH, DCLK3 | NOS2 983/4885NOS1 777/4885BRD4 181/4885 |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | NOS2 2/4885NOS1 3/4885BRD4 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.